title: Histopathological findings of the pancreas, liver, and carbohydrate metabolizing enzymes in STZ-induced diabetic rats improved by administration of myrtenal.
abstract: This study aims to evaluate the efficacy of myrtenal, a natural monoterpene, for its antihyperglycemic effects and β cell protective properties in streptozotocin (STZ)-induced diabetic rats. Oral administration of myrtenal at doses of 20, 40, and 80 mg/kg body weight to diabetic rats for 28 days resulted in a significant reduction (P < 0.05) in the levels of plasma glucose, glycosylated hemoglobin (HbA1c), and an increase in the levels of insulin and hemoglobin (Hb). Protection of body weight loss of diabetic rats by myrtenal was noted. The altered activities of the key metabolic enzymes involved in carbohydrate metabolism such as hexokinase, glucose-6-phosphatase, fructose-1,6-bisphosphatase, glucose-6-phosphate dehydrogenase, and hepatic enzymes AST, ALT, and ALP levels of diabetic rats were significantly improved by the administration of myrtenal in STZ-induced diabetic rats. Moreover, myrtenal treatment improved hepatic and muscle glycogen content in diabetic rats. Histopathological studies further revealed that the reduced islet cells were restored to near-normal conditions on treatment with myrtenal in STZ-induced diabetic rats. An alteration in liver architecture was also prevented by myrtenal treatment. Our results suggest that myrtenal possess antihyperglycemic and β cell protective effects. Hence, myrtenal could be considered as a potent phytochemical for development as a new antidiabetic agent.
authors.affiliation: Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar, 608002, Tamil Nadu, India.
authors.forename: Ayyasamy
authors.initials: A
authors.lastname: Rathinam
authors.forename: Leelavinothan
authors.initials: L
authors.lastname: Pari
authors.forename: Ramasamy
authors.initials: R
authors.lastname: Chandramohan
authors.forename: Bashir Ahmad
authors.initials: BA
authors.lastname: Sheikh
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000081008:Bicyclic Monoterpenes; D050260:Carbohydrate Metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000201:enzymology; D004353:Drug Evaluation, Preclinical; D006597:Fructose-Bisphosphatase / Q000378:metabolism; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D017208:Rats, Wistar; D013311:Streptozocin; D013729:Terpenes / Q000008:administration & dosage*
chemical_list: D000081008:Bicyclic Monoterpenes; D007004:Hypoglycemic Agents; D013729:Terpenes; D013311:Streptozocin; C061545:myrtenal; D006003:Glycogen; D005954:Glucosephosphate Dehydrogenase; D006593:Hexokinase; D006597:Fructose-Bisphosphatase; D005952:Glucose-6-Phosphatase